Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 2, 2009

Beckman Coulter to Pay Clinical Data $17M for Genomic Services Division

  • Beckman Coulter will take over Clinical Data’s Cogenics division for approximately $17 million. Cogenics provides genomics services and has operations in the U.S., U.K., Germany, and France.

    Under terms of the agreement, Clinical Data will receive approximately $15.4 million at the closing, which is expected in April. In addition, it expects to retain approximately $2 million in cash from Cogenics immediately prior to the sale.

    Beckman Coulter points out that the acquisition complements the Agencourt Biosciences business and expands its reach into new territories. Cogenics’ solutions span current and next-generation sequencing, gene expression, clinical and nonclinical genotyping, biomanufacturing support, nucleic acid extraction, as well as biobanking for both research and regulated environments.

    Clinical Data notes that this agreement completes its efforts to monetize noncore assets and focus resources on advancing its therapeutics pipeline. The company expects data from the Phase III evaluation of vilazodone in depression during the second quarter. Additionally, it plans to move Stedivaze, a pharmacologic stress agent for myocardial perfusion imaging, into late-stage testing  this year.

    Clinical Data obtained Stedivaze and reportedly other preclinical and clinical compounds in cardiology, diabetes, inflammatory diseases, and sickle cell anemia through its acquisition of Adenosine Therapeutics for $11 million.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »